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Aims: Toevaluatevalidityandresponsiveness ofPFDIandPFIQshort formsacross fourmulti-center studiesanddevelop
conversionformulasbetweenshortandlongversions.Methods: 1,006participantsinfourprospectivestudiesofpelvicfloor
disorders completed long versions of the PFDI, PFIQ, and SF-36 (or SF-12) at baseline and 3 and 12 months after treatment.
Responses were used to calculate scores for the short versions. We calculated correlations between scale versions using
Pearson’s correlation coefficient and compared their relative responsiveness using the standardized response mean.
Results: PFDI and PFIQ short form scale scores demonstrated excellent correlations with long versions and similar
responsiveness.ResponsivenesswasgoodtoexcellentforPFDI-20urinaryandprolapsescales,moderateforPFDI-20colorectal
scaleandeachofthePFIQ-7scales,andpoor forSF-36(orSF-12)summaryscores.Conversionformulasdemonstratedexcellent
goodness of fit. Conclusions: The long and short forms of the PFDI and PFIQ correlate well and have similar overall
responsiveness in participants from four different prospectivemulticenter studies consisting of diverse patient populations
withabroadrangeofpelvicfloordisorders.Theshortformsprovideareliableandvalidalternativeinsituationswherereduced
response burden is desired. Neurourol. Urodynam. 30:541–546, 2011.  2011 Wiley-Liss, Inc.
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INTRODUCTION
The Pelvic Floor Distress Inventory (PFDI) and the Pelvic Floor
ImpactQuestionnaire (PFIQ) are two complementary condition-
specific health-related quality of life questionnaires for women
withpelvic floor disorders.1 These two instruments are basedon
the structure and content of twowidely-used condition-specific
qualityof lifequestionnairesforwomenwithlowerurinarytract
dysfunction, the Urinary Distress Inventory (UDI) and the
Incontinence Impact Questionnaire (IIQ), whichwere originally
described by Shumaker et al.2 Clinicians and researchers canuse
the PFDI and PFIQ together tomeasure howmuch lower urinary
tract, lower gastrointestinal tract and pelvic organ prolapse
symptoms affect the quality of life of women with pelvic floor
disorders. Each measure has three scales: urinary, colo-rectal
anal, and prolapse. The PFDI and PFIQ have each been shown
to be psychometrically valid, reliable and responsive to
change.1,3,4 The 46-item PFDI assesses symptom distress in
women with pelvic floor disorders and has three scales: the
Urinary Distress Inventory (UDI; range 0–300), the Pelvic
Organ Prolapse Distress Inventory (POPDI: range 0–300), and
the Colorectal-Anal Distress Inventory (CRADI; range 0–400).1
Similarly, the PFIQmeasuring the impact of bladder, bowel, and
vaginal symptoms on a woman’s daily activities, relationships
and emotions is composed of three scales of 31 questions each:
theUrinary ImpactQuestionnaire (UIQ; range 0–400), the Pelvic
Organ Prolapse Impact Questionnaire (POPIQ; range 0–400),
and the Colorectal-Anal Impact Questionnaire (CRAIQ; range
0–400).1
In spite of the strengths of the PFDI and PFIQ, including their
comprehensive coverage of symptom distress and impact on
quality of life, their relative lengthmay be inefficient or imprac-
tical for some clinical or research situations. Table I displays the
itemreductionused todevelop the short formsof thePFDI (PFDI-
20) and PFIQ (PFIQ-7).5 The PFDI-20 and PFIQ-7 demonstrated
excellent correlation with their long-form counterparts in
the original validation population (n ¼ 100) and in a second
independentsampleof45womenundergoingpelvicreconstruc-
tive surgery (r ¼ 0.88–0.94 for scales of PFDI-20; r ¼ 0.95–0.96
for scales of PFIQ-7, P < 0.0001 for all). The test–retest reliability
of each scale in the short formswas good to excellent (ICC 0.70–
0.93,P < 0.001 for all scales).Moreover, the scales and summary
scores of the PFDI-20 and PFIQ-7 demonstrated moderate to
excellent responsiveness 3–6 months after surgery.5
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Inthisanalysis,weplannedto: (1) furtherevaluatethevalidity
and responsiveness of the PFDI-20 and PFIQ-7 (short versions of
thePFDI andPFIQ) across fourmulti-center studiesusingdiverse
patient samples and treatment approaches for pelvic floor dis-
orders and (2) propose formulas for the conversion of scores
between short and long versions of the PFDI and PFIQ.
MATERIALS AND METHODS
We analyzed 1,006 subjects who enrolled in one of four pro-
spectivestudies (twosurgical trials forpelvicorganprolapse,one
non-surgical urinary incontinence trial, and one observational
cohort study of women with fecal incontinence) conducted by
thePelvicFloorDisordersNetwork(PFDN)andcompletedat least
one of the scales of the long-form version of PFDI and PFIQ at
baseline; 84% and 73% of women also completed these at 3 and
12 months post-treatment follow-up. The designs of each trial,
excluding the ongoing observational studyofwomenwith fecal
incontinence,havebeenreportedpreviously.6–10 Inbrief,partici-
pants were: 316women from the CARE trial, a randomized trial
designed to evaluate whether a standardized modified Burch
colposuspension, when added to abdominal sacrocolpopexy to
treat pelvic organ prolapse, improves urinary stress continence
in subjects without preoperative symptoms of stress urinary
incontinence;6,7 140 from the colpocleisis trial, a cohort study
studying theeffect of colpocleisis onpelvic organ support, pelvic
symptoms,qualityof life, report-associatedmorbidity, andpost-
operative satisfaction;8 435 from the ATLAS trial, a randomized
trial comparingbehavioral therapy, incontinence pessary, anda
combination of the two for treatment of stress urinary incon-
tinence;9 115 from ABBI trial, an observational cohort study
focusing on describing the use of adaptive behaviors among
women undergoing treatment for fecal incontinence. Each
clinical site and the data coordinating center in PFDN received
institutional review board approval for each of the four trials,
and all subjects provided written informed consent.
In each study, the instruments were administered either by
telephone or inperson at baseline and3 and12months after the
intervention. Participant responses to the PFDI and PFIQ indi-
vidual items that are included in the short form versions were
used to calculate the scores for PFDI-20 and PFIQ-7 scales includ-
ing urinary, prolapse, and colo-rectal/anal subscales. The scales
of PFDI-20 and PFIQ-7 (UDI-6, POPDI-6, CRADI-8; UIQ-7, POPIQ-7,
CRAIQ-7) all have a range of 0–100, which is different than the
scales of their long-form counterparts.5
In addition, participants in all the trials, except women with
fecal incontinence participating in ABBI, completed the SF-36, a
generic health-related quality of life questionnaire.11 Instead,
ABBI participants completed the SF-12, a shortened validated
version of the SF-36. The generic health instrument, SF-36 or
SF-12, was considered a priori for this ancillary analysis andwe
selected two summary scales, the mental and physical com-
ponents. For both the long and short form versions PFDI and
the PFIQ, a higher score indicates worse symptom bother or
greater impact of symptoms on daily functioning; for the scales
of the SF-36 or SF-12, a higher score indicates better health-
related quality of life.1,11
For all analyses, we used each separate study population, as
well as a combined group formed by pooling the 1,006 study
participants from the four studies. In particular, the summary
scores of the SF-12were analyzed forABBI and the SF-36 for each
of other three trials first, and then the SF-12 and SF-36 were
pooled together for the across-study combined sample.12 The
correlations between the corresponding scales of the long- and
short-form versions of the PFDI and PFIQ at baseline were esti-
matedusing Pearson’s correlation coefficients. In order to evalu-
ate the relative responsiveness of the scales of PFDI, PFIQ, PFDI-
20, PFIQ-7, and SF-36 and/or SF-12, the standardized response
mean (SRM) of the change in scores from baseline to 3 months
and baseline to 12months after intervention for each scale was
assessed; the SRMs were compared between the corresponding
scales of the long and short forms of PFDI and PFIQ, between the
condition-specific HRQOL (long- and short-form version of PFDI
and PFIQ) and the generic HRQOL (SF-36 and/or SF-12) in a
descriptive and exploratory fashion. SRM, a commonly used
statistic of responsiveness, is equivalent to the change in score
over a time period divided by the standard deviation of the
change.13 A higher SRM (in absolute value) indicates better
responsiveness. A value of 0.5 is a cutoff for a moderate respon-
siveness, 0.8 a good responsiveness, and 1.0 an excellent one.13
We also used simple linear regression modeling to develop
conversion formulas to calculate the scale scores of the PFDI and
PFIQ long form from the short versions of the questionnaires.
Each subscale of the PFDI or PFIQ short form was regressed on
that of the long form and only the statistically significant
parameters (i.e., intercept and slope) were retained in the final
model. Themodel assumptionswere examinedgraphically (e.g.,
linearity, normality, and influence cases) and R2 values were
reported. A split-sample validation method was used to assess
the predictive accuracy of the conversion formulas.14,15 The
entire analysis sample (n ¼ 1,006) was first stratified by study
(condition-specific patient population), then within each study
the sample was evenly partitioned into a training set (model
development) and a test set (model validation) in a random
fashion. The respective stratum-specific sets were recombined
intoafinaltrainingsetandafinaltestset.Thesamelinearmodels
were developed from the training sample and then cross-vali-
dated in the test sample.14,15 Discrimination was assessed by
comparing the R2 in the training set to that achieved in the test
set.Thiswasobtainedbyapplyingthe linearmodelderivedfrom
the training sample to the test sample to yield a predicted long
form score and then correlated it with the observed long form
scale score in the test sample.14 The model’s calibration was
validated graphically in the test set aswell.14 Based on the small
shrinkage (the difference between R2 of the training sample
and R2 of the test sample) and the calibration plot, the training
TABLE I. Comparison Between Short and Long Versions of the PFDI and PFIQ
Original questionnaire Original scales No. of items Short form Scales No. of items
PFDI 46 PFDI-20 20
Urinary distress inventory (UDI) 28 UDI-6 6
Pelvic organ prolapse distress inventory (POPDI) 16 POPDI-6 6
Colorectal-anal distress inventory (CRADI) 17 CRADI-8 8
PFIQ 93 PFIQ-7 21
Urinary impact questionnaire (UIQ) 31 UIQ-7 7
Pelvic organ prolapse impact questionnaire (POPIQ) 31 POPIQ-7 7
Colorectal-anal impact questionnaire (CRAIQ) 31 CRAIQ-7 7
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and test sets were combined for fitting the ‘‘final’’ proposed
models.14,15 The proposed conversion formulas were based on
the pooled sample across the four studies.
All reported P values were based on the two-sided statistical
tests. The analyses were performed in SAS 9.1.3 for Windows
(SAS, Inc., Cary, NC).
RESULTS
Table II summarizes the demographics and baseline charac-
teristics of the four study cohorts used in these analyses.6–10
Variations inprevalence rates forurinaryandfecal incontinence
are representative of the inclusion criteria for each study.
Overall, the rate of missing data was low for all studies at base-
line (0.5–2%). All participants provided responses to at least one
of the long-versionscalesof thePFDI, PFIQ,andSF-36 (orSF-12) at
baseline, with 84% (849/1,006) available at 3 months and 73%
(738/1,006) available at 12 months.
The overall pooled correlation coefficients between the long
formsandselectedquestions representing theshortormversion
ofthePFDIandPFIQatbaselineareshowninTableIII.Overall, the
correlation coefficients between the short and long version
scores pooled across the four populations were excellent, with
all subscales having Pearson’s correlations of greater than 0.88
(all P < 0.0001).
Responsiveness to change of the PFDI and PFIQ short form
scaleswassimilartothatofthelongversionsacrossall fourstudy
populations (Table IV). In the pooled sample, the urinary and
prolapse scales of the PFDI-20 demonstrated good responsive-
ness at 3 and 12months (SRM0.71 to0.85). The highest SRM
values were found in the POPDI responses collected from
women enrolled in the surgical trials for treatment of prolapse
(CARE ¼ 1.35 at 3 months and 1.42 at 12 months; and
Colpocleisis ¼ 1.68 at 3 and 12 months) while the lowest
SRM values were found in the POPDI responses from women
enrolled in the fecal incontinence study (ABBI ¼ 0.44 at
3months) andwomen enrolled in the trial seeking conservative
therapyforstress incontinence (ATLAS ¼ 0.42at12months) in
the ABBI trial (evaluating behavior responses to fecal inconti-
nence)andat12months (0.42) in thePOPDI responses fromthe
population of women enrolled in the ATLAS trial. Overall, the
colorectal subscaleof thePFDI-20demonstrated fair tomoderate
responsiveness across the three populationswith primarily uri-
nary and prolapse symptoms; however, in the group of women
with fecal incontinence (ABBI trial), responsiveness to change
wasgoodat3monthsandexcellentat12months(SRM0.73and
1.09, respectively).
Each of the scales of the PFIQ-7 demonstrated a broad range of
SRMfrom0.21to0.90,withhigherSRMsintheUIQandCRAIQ
for thewomenwithurinaryandfecal incontinence respectively.
ThelowestvalueswereinthePOPIQscoresfromtheATLASgroup
(SRM ¼ 0.23 at 3months and0.21 at 12months), however these
values were markedly better in the population of women
TABLE II. Demographic and Baseline Characteristics by Study and Overall
CARE trial Colpocleisis cohort ATLAS trial ABBI cohort Total
N 316 140 435 115 1,006
Primary condition studied Pelvic organ prolapse Pelvic organ prolapse Stress urinary incontinence Fecal incontinence —
Age (mean  SD) 61.4  10.3 79.2  5.3 49.7  11.9 57.8  13.9 58.4  14.7
Race (%)
White/Caucasian 294 (93.0%) 129 (92.1%) 369 (85.0%) 99 (86.1%) 891 (88.7%)
Black/African American 16 (5.1%) 11 (7.9%) 45 (10.4%) 13 (11.3%) 85 (8.5%)
Other 6 (1.9) 0 (0.0%) 20 (4.6%) 3 (2.6%) 29 (2.9%)
Hispanic ethnicity (%) 9 (2.9%) 1 (0.7%) 32 (7.4%) 9 (7.8%) 51 (5.1%)
Educational level (%)
Less than high school 26 (8.2%) 32 (22.9%) 18 (4.1%) 9 (7.9%) 85 (8.5%)
Completed high school or equivalent 121 (38.3%) 63 (45.0%) 81 (18.6%) 31 (27.2%) 296 (29.4%)
Some college or higher 169 (53.5%) 45 (32.1%) 336 (77.2%) 74 (64.9%) 624 (62.1%)
Body mass index (kg/m2) (mean  SD) 27.0  4.5 27.8  5.4 29.5  6.8 29.0  7.0 28.4  6.1
Parity (median, range) 3 (1, 11) NA 2 (0, 11) 3 (0, 9) 2 (0, 11)
Stress urinary incontinence (%)a 60 (19.1%) 105 (75.0%) 430 (99.3%) 77 (67.0%) 672 (67.1%)
Urge urinary incontinence (%)b 87 (27.5%) 91 (65.0%) 183 (42.5%) 69 (60.0%) 430 (42.9%)
Pelvic organ prolapse stage (%)c
Stage 0/1 0 (0.0%) 0 (0.0%) 249 (57.9%) NA 249 (28.3%)
Stage 2 44 (13.9%) 0 (0.0%) 181 (42.1%) 225 (25.5%)
Stage 3/4 272 (86.1%) 135 (100.0%) 0 (0.0%) 407 (46.2%)
Fecal incontinence (%)d 64 (20.3%) 44 (31.4%) 104 (24.0%) 104 (90.4%) 316 (31.4%)
NA, data not available.
aDefined as any affirmative response to one of the three items in the stress subscale of the Pelvic Floor Distress Inventory (PFDI).
bDefinedasanaffirmativeresponsetoitem19 ‘‘Doyouusuallyexperienceurine leakageassociatedwithafeelingofurgency, that is,astrongsensationofneeding
to go to the bathroom?’’ or item 28 ‘‘Do you usually experience bed-wetting?’’ of the PFDI.
cPelvic organ prolapse quantitation (POPQ) stage.26
dDefined as an affirmative response to item38 ‘‘Do you usually lose stool beyond your control if your stool iswell formed?’’ or item39 ‘‘Do you lose stool beyond
your control if your stool is loose or liquid?’’ of the PFDI.
TABLE III. Pearson Correlation Between Long and Short Form Versions of
PFDI and PFIQ At Baseline
Scale Subscale N Coefficient (rangea) P-Value
PFDI UDI 1,001 0.88 (0.81, 0.93) <0.0001
POPDI 1,000 0.90 (0.86, 0.90) <0.0001
CRADI 984 0.93 (0.91, 0.94) <0.0001
PFIQ UIQ 995 0.96 (0.95, 0.98) <0.0001
POPIQ 994 0.98 (0.97, 0.99) <0.0001
CRAIQ 997 0.98 (0.97, 0.98) <0.0001
N, Pearson coefficient and P-value are frompooled sample across four studies.
aThe range of Pearson correlation across four studies.
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undergoing prolapse surgery (greater than 0.60 at 3 and
12 months for both the CARE and Colpocleisis groups). In con-
trast, the SF-36 summary scoreswere relatively unresponsive to
change (Table IV).
Conversion formulas to estimate long form scale scores were
developed from PFDI-20 and PFIQ-7 questions within the base-
linequestionnaires. Eachequationdemonstratedgoodness offit
ranging from R2 values of 0.78–0.96 (Table V). For instance, the
formula to convert the urinary scale of the PFDI-20 to the long
form score is UDI score ¼ 1.9  UDI-6 score þ 11. To ensure the
validity and reliability of the conversion formulas, ‘‘one-time
data-splitting’’ was employed. Evidence of a good internal
validity was confirmed by the similarity in R2 values in the
development and validation samples (Table V). The calibration
(or reliability) and discrimination jointly demonstrated that the
derived formulas had good predictive accuracy.13
DISCUSSION
We found excellent correlation between the long and short
forms of the Pelvic Floor Distress Inventory (PFDI) and the Pelvic
Floor ImpactQuestionnaire (PFIQ), allowing scientifically sound
use of these short forms for clinical or research purposes. Barber
et al.1 reported that it took an average (SD) of 23  11 min to
administer both the 46-item PFDI and 93-item PFIQ. The use of
short forms instead can reduce participant burden in research
settings,as thePFDIandPFIQareoftenused incombinationwith
other self-reported measures of interest.
Findings regarding the responsiveness of the short formsover
timewere generally very positive,with the PFDI-20 that focuses
on symptom distress, the urinary and prolapse subscales dem-
onstrating good to excellent responsiveness across populations.
Not surprisingly, condition specific subscales of each question-
naire were the most responsive to the respective pelvic floor
disorderofprimary interest. For example, thecolorectal subscale
was somewhat more varied with fair to moderate responsive-
nessacrosspopulationsofwomenpresentingwithprolapseand
urinary incontinence, but good to excellent responsiveness in
women presenting with a primary complaint of fecal inconti-
nence (SRM 0.73 and 1.09) at 3 and 12months, respectively.
Similarly, the SRM values for symptom distress POPDI were the
highestwhen the studypopulation of interestwas prolapse and
lowestwhen itwasnot theprimaryoutcome. In thePFIQ-7 short
form, that focusesonthe impactof symptomsondailyactivities,
the responsiveness of the subscales showed greater variability
across patient populations and treatments, with better respon-
siveness in studies involving prolapse surgery. In the original
validation for the short forms, the responsiveness for theCRADI-
8 and the CRAIQ-7 were lower than the other subscales, with
SRMs of 0.70 and 0.51, respectively.3 Our findings using a larger
cohort ofwomenundergoing specific treatment for pelvic organ
prolapse,urinary incontinence, and fecal incontinence suggest a
lower responsivenessof thecolorectal subscale in comparison to
the other subscales (i.e., SRM for CRADI-8 ¼ 0.46 and CRAIQ-
7 ¼ 0.37). These lower levels of responsiveness may be
accounted for by an overall lower burden of colorectal disease
among themajority of thewomen in the combined groupswho
presentedfor treatment forpelvicorganprolapseand/orurinary
incontinence. The majority of the women in these multi-center
studies were participating in specific intervention studies for
pelvic organ prolapse, with and without stress urinary incon-
tinence, with fewer women reporting fecal incontinence. No
specific randomized, controlled treatments for colorectal dis-
orders suchas fecal incontinencewereprovided in these studies,
althoughsomewomenwithfecal incontinencedidreceivetreat-
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studiesmayhave experienced some improvement in colo-rectal
symptoms with the treatments under study. Our finding that
there is good responsiveness of theCRADIandCRAIQ in theABBI
study that specifically enrolled patientswith fecal incontinence
supports the use of these scales in this population. Several other
qualityof lifequestionnaires forwomenwith fecal incontinence
exist including the Fecal IncontinenceQuality of Life Scale16 and
theModifiedManchester Questionnaire,17 however the respon-
siveness of these instruments have not been evaluated. Future
studies should be performed to determine the relative respon-
siveness of these various instruments.
Asanticipated,we found thatboth the longandshort formsof
the PFDI and PFIQ were more responsive to change than the SF-
36/SF-12 physical and mental component summary scores. In
the initial validation of the PFDI-20 and PFIQ-7, low responsive-
nesswas reported for thementalandphysical componentscores
on the SF-36 (SRM range 0.12 and 0.28, respectively).3 Our find-
ings across four studies found similarly low responsiveness at 3
and 12 months follow-up for the SF-36 mental (SRM 0.12 and
0.14)andphysicalcomponentscores (SRM0.15and0.26)respect-
ively. These findings are consistentwith previous studies show-
ing limited responsiveness of generic QOLmeasures such as the
SF-36 compared to condition-specific measures for women
treated for pelvic floor disorders.18–21 The responsiveness of
the SF-36 in studies involving other chronic diseases are some-
whatmixed,22–24 but in large part they are less responsive than
condition-specific measures.25
The conversion scores reported in our study are intended for
use in clinical and research settings for comparing outcomes
measured with the PFDI-20 and PFIQ-7 to themore comprehen-
sive instruments. The conversion formulas were developed for
use in well-described, clinically relevant patient populations,
such as women with specific degrees of pelvic organ prolapse
with and without stress urinary incontinence, as well as fecal
incontinence, andmaynot apply to general clinical populations
of womenwithout pelvic floor disorders.7–10 Therefore, investi-
gators should use caution in extrapolating these formulas to
other populations.
Our use of four multi-center studies with varying patient
demographics, disease characteristics, and treatments is a
strength and allows more generalizability of our findings.
Another strength of the study is the use of multiple modalities
via self-reportedand telephone interviews for administrationof
the PFDI and PFIQ long forms. Additionally, we developed and
validatedconversionformulasbetweentheshortandlongforms
that should be of benefit to researchers and clinicians. Although
we derived scores for the short forms from responses to the long
form rather than comparing subject responses from the short
form itself, we believe this is aminor limitation. However, since
subjects did not complete both questionnaires, we could not
performdirect comparisons or evaluate issues of question order,
question fatigue, and item grouping. Another limitation is that
themeasures of responsiveness used in this trial depend in part
on the effectiveness of the interventions used. Our analysis of
responsiveness includedall patients in the four trials considered
who completed questionnaires at baseline and follow-up,
whether their treatment resulted insymptomatic improvement
or not. As such, the responsiveness statistics reported likely
represent conservative estimates.
Despite the very positive findings from this study advocating
for use of the PFDI and PFIQ short forms in research and clinical
settings, there may be some circumstances where the long ver-
sions of the PFIQ and PFDI are preferable. For example, the long
formsmaybepreferablewhenamorecomprehensive inventory
of symptomdistress and impactofpelvicfloordisordersondaily
activities is a primary study aim. In such cases, the long version
could provide better characterization across the full spectrumof
the disorder. A generic QOL measure such as the SF-36 or SF-12
may also be desirable if comparability of findings across popu-
lations is warranted.
CONCLUSIONS
In conclusion, the PFDI-20 and PFIQ-7 scales are well-corre-
latedwith thePFDI andPFIQ long formsandhave similar overall
responsiveness in four different prospective studies. Our find-
ings provide further evidence that these short forms can be
applied to studies that vary in intervention focus and type of
pelvic floor disease. These short forms are excellent alternatives
to PFDI and PFIQ when decreased response burden is desired in
research and clinical settings.
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